Gliomas are a type of brain tumor that are particularly dangerous, especially for younger adults, as they are a leading cause of cancer-related deaths in this group. One common genetic mutation found in about 7,000 patients affects an enzyme called isocitrate dehydrogenase 1 (mIDH1). This mutation leads to the production of a molecule called 2-hydroxyglutarate, which can alter the behavior of tumor cells and the surrounding tissue. It can also travel through the bloodstream and influence immune cells in the bone marrow. Although there are drugs approved by the FDA that can block the production of this molecule, these gliomas often return, and when they do, they are usually difficult to treat. In a study published in Nature Communications, researchers at the University of Michigan discovered a new way to make mIDH1 gliomas more responsive to radiation therapy. They used both human glioma cells obtained from biopsies and mouse models with tumors that closely resembled the human condition. The study found that these glioma cells had increased autophagy, a process that helps cells remove waste and maintain internal balance. However, the mIDH1 glioma cells were resistant to radiation therapy, a common treatment for brain tumors, because they had enhanced DNA repair mechanisms. Maria Castro, a professor of neurosurgery and researcher at the Rogel Cancer Center, explained that these tumors grow slowly because their autophagy helps them manage cellular waste more efficiently. Their strong DNA repair abilities also make them less vulnerable to radiation, which typically damages DNA to kill cancer cells. Targeting these pathways with chemotherapy has been difficult due to the blood-brain barrier, which prevents most drugs from reaching the brain. Autophagy inhibitors also face this challenge and can cause harmful side effects. To overcome this, the researchers developed nanoparticles that can be injected into the bloodstream. These nanoparticles carry small RNAs that can block the autophagy pathway. Joerg Lahann, a professor of chemical engineering, noted that using nanoparticles to deliver these small RNAs is a novel approach that allows the drugs to effectively reach and act on brain tumors. In their experiments, the researchers found that when they inhibited autophagy and combined it with radiation therapy, 60% of the mice were cured of their tumors and remained tumor-free for a long time. The nanoparticles used in the study did not cause any toxic side effects. When the researchers implanted a new tumor in mice that had already cleared their initial tumors, the mice were able to eliminate the new tumors without further treatment. This was due to the presence of specific T cells that had "memory" of how to fight the tumor. These immune cells remain inactive after the initial cancer is destroyed but become active again when the tumor returns, helping to eliminate it. Castro and her team are now working to better understand the molecular processes that lead to the body’s immune response against tumors. Gaining insight into how immunological memory is formed could help prevent cancer from returning. The team is also planning phase 1 clinical trials to test a treatment that combines radiation therapy with their engineered nanoparticles, which could offer a new approach for treating these challenging brain tumors.